Illumina Ventures is an independently managed venture capital firm focused on early-stage companies pioneering new applications of genomics and precision medicine. The firm invests in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health, and operates in strategic partnership with Illumina, Inc., which provides the majority of its capital.
56% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (6 deals in the last 12 months). Average disclosed round size is $61.5M (across 81 rounds with reported amounts).
Portfolio
60
Fund Size
$325M
Top Stage
Series A
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
100 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Encoded Therapeutics | Series F | $275M | Sep 2026 |
 Syntax | Series A | $14.4M | Jun 2026 |
| AAlamar Biosciences, Inc. | Ipo | $219.9M | Apr 2026 |
 Precede Bio | Series B | $63.5M | Jan 2026 |
 SonoThera | Series B | $125M | Jan 2026 |
 Lightcast | Unknown | $27M | Jan 2026 |
| Encoded Therapeutics | Series F | $275M | Jan 2026 |
| EEncoded | Series F | $275M | Jan 2026 |
 MyOme, Inc. | Unknown | — | Dec 2025 |
 Predicta Biosciences | Series A | $23.4M | Oct 2025 |
 NuCicer | Series A | $11.5M | Jul 2025 |
 Infinity Bio | Series A | $8M | Jul 2025 |
 Arima Genomics | Series C | $22M | Jun 2025 |
| AArima Genomics | Series C | $22M | Jun 2025 |
 Pillar Biosciences | Series B | $34.5M | May 2025 |
| Infinity Bio | Series A | $8M | Jan 2025 |
| Pillar Biosciences | Series C | $64M | Jan 2025 |
 Human Longevity Inc (HLI) | Series B | $39.8M | Aug 2024 |
| Predicta Biosciences | Seed | — | Jul 2024 |
 Iambic Therapeutics | Unknown | $50M | Jun 2024 |
 Attovia Therapeutics | Series B | $105M | May 2024 |
| AAlamar Biosciences, Inc. | Series C | $128M | Feb 2024 |
| Iambic Therapeutics | Series B | $220M | Jan 2024 |
 Actym Therapeutics | Series A | $59.5M | Oct 2023 |
| Precede Bio | Series A | $57M | Oct 2023 |
Page 1 of 4
Top Co-Investors
ARCH Venture Partners17 shared
Samsara BioCapital12 shared
Menlo Ventures11 shared
Alexandria Venture Investments10 shared
Osage University Partners9 shared
M Ventures9 shared
Kurma Partners9 shared
AV8 Ventures9 shared
Windham Capital Partners9 shared
Agilent Technologies8 shared
Idinvest Partners8 shared
Northpond Ventures8 shared
T. Rowe Price8 shared
GV7 shared
OrbiMed7 shared
Casdin Capital6 shared
Catalio Capital Management6 shared
Cowen Healthcare Investments6 shared
Foresite Capital6 shared
Rock Springs Capital6 shared
Last updated: 20 October 2026